OpenURL Connection Search

Select item for more details and to access through your institution.

Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up.
Published in:
2018
By:
- Kougkas, Nikolaos;
- Fanouriakis, Antonis;
- Papalopoulos, Ioannis;
- Bertsias, George;
- Avgoustidis, Nestor;
- Repa, Argyro;
- Sidiropoulos, Prodromos
Publication type:
Letter to the Editor
Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.
Published in:
Rheumatology International, 2021, v. 41, n. 10, p. 1833, doi. 10.1007/s00296-021-04887-3
By:
- Kougkas, Nikolaos;
- Bertsias, George;
- Papalopoulos, Ioannis;
- Repa, Argiro;
- Sidiropoulos, Prodromos;
- Avgoustidis, Nestor
Publication type:
Article
Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients.
Published in:
Therapeutic Advances in Musculoskeletal Disease, 2020, p. 1, doi. 10.1177/1759720X20937132
By:
- Thomas, Konstantinos;
- Lazarini, Argiro;
- Kaltsonoudis, Evripidis;
- Drosos, Alexandros;
- Papalopoulos, Ioannis;
- Sidiropoulos, Prodromos;
- Tsatsani, Panagiota;
- Gazi, Sousana;
- Pantazi, Lina;
- Boki, Kyriaki A.;
- Katsimbri, Pelagia;
- Boumpas, Dimitrios;
- Fragkiadaki, Kalliopi;
- Tektonidou, Maria;
- Sfikakis, Petros P.;
- Karagianni, Konstantina;
- Sakkas, Lazaros I.;
- Grika, Eleftheria P.;
- Vlachoyiannopoulos, Panagiotis G.;
- Evangelatos, Gerasimos
Publication type:
Article
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
Published in:
Arthritis Research & Therapy, 2022, v. 24, n. 1, p. 1, doi. 10.1186/s13075-022-02826-6
By:
- Bertsias, Antonios;
- Avgoustidis, Nestor;
- Papalopoulos, Ioannis;
- Repa, Argyro;
- Kougkas, Nikolaos;
- Kalogiannaki, Eleni;
- Bertsias, Georgios;
- Flouri, Irini;
- Sidiropoulos, Prodromos
Publication type:
Article

Found: 4

Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up.

Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review.

Treatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patients.

Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.